Objective To analyze the risk factors of acute organophosphate pesticide poisoning intermediate syndrome(IMS ),and discuss the corresponding nursing countermeasures. Methods From January 2007 to January 2011,50 cases of patients with acute organophosphate pesticide poisoning were collected as the research object.And we analyzed the risk factors of related intermediate syndrome. Results The incidence rate of acute organophosphate poisoning intermediate syndrome was 10.0％.IMS mainly occurred at age of 20～50 years old,rarely occurred at age of ＜20 and ＞50 years old.The incidence of IMS with oral intake was higher than respiratory poisoning and skin poisoning.The incidence of IMS caused by drugs of moderate toxicity was higher than drugs with high or low toxicity.The incidence of IMS patients who got atropinization within 2 hours was less than those without it.The incidence of IMS patients using aminoglycoside drugs was higher than those not using them. Conclusions Poisoning way,toxicity of toxicant,timely treatment,basic diseases,atropinization within 2 hours,and using aminoglycoside drugs can influence the condition and prognosis of intermediate syndrome caused by organophosphate pesticide poisoning.

Diabetic neuropathy is the most common peripheral neuropathy,and it is important to enhance both nerve regeneration and prevent nerve degeneration in its treatment. Disturbed nerve regeneration in diabetes has been ascribed,at least in part,to decreases of some neurotrophic factors or the decreases of their receptor expressions.This paper reviewed the effect of some major neurotrophic factors on diabetic neuropathy and their application in clinical treatment.

OBJECTIVE:To evaluate economic effectiveness of 3 kinds of antimicrobial drugs for acute lithiasic cholecystitis,and to provide reference for rational use of antimicrobial drugs in biliary disease surgery.METHODS:A multicenter prospective randomized controlled study was conducted in 493 clinical cases of acute lithiasic cholecystitis.Cost-effectiveness analysis of cefoperazone/sulbactam sodium(therapy A n=180),cefuroxime(therapy B n=148) and levofloxacin(therapy C n=165) for acute lithiasic cholecystitis were carried out.RESULTS:Effective rates of three kinds of therapeutic regimens 95.56%,73.65%,84.24%,respectively.CONCLUSION:Incremental cost-effectiveness analysis of three kinds of therapeutic regimens shows therapy A is economical and the best choice for acute lithiasic cholecystitis compared with group B and C.

Objective To observe efficacy of Pulmicort in treatment of capillary bronchitis.Methods Children with capillary bronchitis were randomly divided into two groups,ninty-eight cases of study group were treated with Pulmicort,fifty-eight cases of control group were treated with common therapy,observe clinical symptom:cough,breathes heavily. Results Two groups efficiency were 93.8% and 72.4% respectively.The study group was significantly better than that in control group. Conclusion Pulmicort inhalation in treatment of children with capillary bronchitis are effective.

ObjectiveTo test the antifungal activity of berberine (BBR) against Candida albicans in vitro. MethodsAccording to the National Committee for Clinical Laboratory Standards (NCCLS) M27-A protocol, broth microdilution test was performed to assess the susceptibility of 30 clinical isolates of Candida albicans to BBR and fluconazole alone or in combination. ResultsThe geometric mean minimum inhibitory concentration (MIC) was 248.18 mg/L and 2.64 mg/L for BBR and fluconazole alone, respectively. When combined with BBR of 320, 160 and 80 mg/L, the geometric mean MIC decreased to 0.03, 0.35 and 1.35 mg/L respectively for fluconazole. Fluconazole and BBR showed synergistic effects in 26.7％ of these isolates including 3 fluconazoleresistant strains, additive effects in 56.7％, indifferent effects in 16.7％, antagonistic effects in none. Conclu sionIn vitro, BBR has antifungal activity against Candida albicans and can enhance the activity of fluconazole against Candida albicans.

The innovation of medical technology and progress of health care are dependent on the effectiveness of hospital scientific research management.By integrating the concept of refined management and with the construction of research platforms,an innovative administration mode for hospital research management was established and a sustainable development of hospital scientific research administration becomes possible.

Objective To explore the causes of bone fascia compartment syndrome after radial artery coronary artery intervention and sum up the nursing experience. Method The clinical data of 8 patients with bone fascia compartment syndrome after radial artery coronary artery intervention from January 2009 to December 2014 were analyzed retrospectively to summarize the nursing countermeasures, including close observation of illness, swelling and pain nursing, medication and blood and monitoring of coagulation functions. Result The forearm of all patients were painful, swollen and enlarged, 6 of them with radial pulse abating,1 with finger pulling pain, 2 with muscle decreasing. Conclusions The early observation and treatment of bone fascia compartment syndrome are critical. Great importance to the complaints of patients should be attached in view of the causes of complications so that effective nursing strategy can be taken to save time of conservative treatment, alleviate the patients'pains and promote their early recovery.

The identification traumatic cataract must be based on the optical dysopia after ocular injuries. 72 cases of traumatic cataract were classified into 3 groups according to the classification of WHO about optical dysopia. There were 9 cases low vision, 58 cases blind and 5 incorporated cases after injuries. After operation, there were 12 cases that stenopeic spectacles vision was 0.4～1.2, 29 cases were low vision, 26 cases blind. The results suggested that the vision of traumatic cataract could be changed after operation, and the best time for forensic identification could be 1 or 2 months after operation.

DNA, Circular ; blood ; Hepatitis B ; blood ; drug therapy ; virology ; Hepatitis B Surface Antigens ; blood ; Hepatitis B virus ; Humans ; Nucleosides ; therapeutic use